Feasibility of Community Pharmacist-Initiated and Point-of-Care

Humans Acute Coronary Syndrome / drug therapy Clopidogrel / therapeutic use Cytochrome P-450 CYP2C19 / genetics Feasibility Studies Genotype Pharmacists Platelet Aggregation Inhibitors / therapeutic use Point-of-Care Systems Prasugrel Hydrochloride / therapeutic use Ticagrelor / therapeutic use Purinergic P2Y Receptor Antagonists / therapeutic use
CYP2C19 P2Y12 inhibitor clopidogrel dual antiplatelet therapy personalized medicine pharmacogenetics pharmacogenomics point-of-care testing

Journal

Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097

Informations de publication

Date de publication:
25 02 2023
Historique:
received: 07 02 2023
revised: 16 02 2023
accepted: 21 02 2023
medline: 30 3 2023
entrez: 29 3 2023
pubmed: 30 3 2023
Statut: epublish

Résumé

Tailoring antiplatelet therapy based on

Identifiants

DOI: 10.3390/genes14030578 PMID: 36980851 PMC: PMC10048116
pubmed: 36980851
pii: genes14030578
doi: 10.3390/genes14030578
pmc: PMC10048116
pii:
doi:

Substances chimiques

Clopidogrel A74586SNO7
CYP2C19 protein, human EC 1.14.14.1
Cytochrome P-450 CYP2C19 EC 1.14.14.1
Platelet Aggregation Inhibitors 0
Prasugrel Hydrochloride G89JQ59I13
Ticagrelor GLH0314RVC
Purinergic P2Y Receptor Antagonists 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Per Med. 2016 Mar;13(2):119-127
pubmed: 29749904
Pharmacogenomics. 2017 Mar;18(4):327-335
pubmed: 28244804
Pharmacogenomics. 2018 May;19(7):621-628
pubmed: 29701129
Eur Heart J. 2010 Dec;31(24):3046-53
pubmed: 20833683
Eur Heart J Acute Cardiovasc Care. 2015 Dec;4(6):499-508
pubmed: 25515725
J Am Pharm Assoc (2003). 2014 Mar-Apr;54(2):172-80
pubmed: 24632932
J Am Pharm Assoc (2003). 2011 Mar-Apr;51(2):189-93
pubmed: 21382809
Clin Pharmacol Ther. 2012 Mar;91(3):450-8
pubmed: 22278335
Eur Heart J Acute Cardiovasc Care. 2016 Feb;5(1):3-12
pubmed: 25561688
Clin Pharmacol Ther. 2017 Mar;101(3):341-358
pubmed: 28027596
P T. 2018 Jun;43(6):352-357
pubmed: 29896034
JACC Cardiovasc Interv. 2018 Jan 22;11(2):181-191
pubmed: 29102571
Pharmacogenomics. 2012 Jun;13(8):955-62
pubmed: 22676199
Pharmacogenomics J. 2022 Dec;22(5-6):303-307
pubmed: 35449399
Res Social Adm Pharm. 2022 Jul;18(7):3094-3118
pubmed: 34474980
N Engl J Med. 2009 Sep 10;361(11):1045-57
pubmed: 19717846
J Thromb Haemost. 2013 Jan;11(1):81-91
pubmed: 23137413
Am J Prev Med. 2022 Oct;63(4):636-646
pubmed: 35688723
N Engl J Med. 2019 Oct 24;381(17):1621-1631
pubmed: 31479209
Res Social Adm Pharm. 2021 Apr;17(4):744-749
pubmed: 32741696
Pharmacogenomics. 2012 Sep;13(12):1419-25
pubmed: 22966890
J Am Pharm Assoc (2003). 2014 Sep-Oct;54(5):510-7, 5 p following 517
pubmed: 25148656
Pharmacogenet Genomics. 2019 Jun;29(4):76-83
pubmed: 30724853
Clin Pharmacol Ther. 2022 Nov;112(5):959-967
pubmed: 35034351
Eur Heart J. 2018 Jan 14;39(3):213-260
pubmed: 28886622
Genet Med. 2020 Jan;22(1):160-169
pubmed: 31316169
EuroIntervention. 2017 Jul 20;13(4):459-466
pubmed: 28374678
Am J Cardiovasc Drugs. 2022 May;22(3):287-298
pubmed: 34651261
Circ Cardiovasc Genet. 2014 Dec;7(6):895-902
pubmed: 25258374
N Engl J Med. 2007 Nov 15;357(20):2001-15
pubmed: 17982182
Eur Heart J. 2013 Mar;34(12):909-19
pubmed: 23315904
J Pers Med. 2020 Dec 24;11(1):
pubmed: 33374349
Eur Heart J. 2021 Apr 7;42(14):1289-1367
pubmed: 32860058
Eur Heart J. 2011 Dec;32(23):2933-44
pubmed: 22090660
Circulation. 2009 Jun 2;119(21):2758-64
pubmed: 19451347
J Am Coll Cardiol. 2018 Jan 30;71(4):371-381
pubmed: 29154813
Circ Genom Precis Med. 2020 Feb;13(1):e002640
pubmed: 31928229
JACC Cardiovasc Interv. 2019 Aug 26;12(16):1521-1537
pubmed: 31202949
Heart. 2016 Apr;102(8):617-25
pubmed: 26848185
Stroke Vasc Neurol. 2021 Jun;6(2):274-279
pubmed: 33952669
Lancet. 2021 Oct 9;398(10308):1305-1316
pubmed: 34627490
Lancet. 2017 Oct 14;390(10104):1747-1757
pubmed: 28855078
J Pers Med. 2020 Dec 21;10(4):
pubmed: 33371313
Circ Cardiovasc Interv. 2019 Apr;12(4):e007811
pubmed: 30998396
Genes (Basel). 2019 May 29;10(6):
pubmed: 31146504
Pharmacogenomics J. 2018 Jan;18(1):113-120
pubmed: 28117433
J Clin Med. 2020 Mar 17;9(3):
pubmed: 32192029
JAMA. 2010 Oct 27;304(16):1821-30
pubmed: 20978260
Ann Pharmacother. 2005 Oct;39(10):1720-5
pubmed: 16144881
JAMA. 2020 Aug 25;324(8):761-771
pubmed: 32840598
N Engl J Med. 2014 Dec 4;371(23):2155-66
pubmed: 25399658
J Transl Med. 2018 Apr 11;16(1):92
pubmed: 29642909
Public Health Genomics. 2014;17(5-6):287-98
pubmed: 25401385
J Am Coll Cardiol. 2008 May 27;51(21):2028-33
pubmed: 18498956
J Am Coll Cardiol. 2018 Dec 11;72(23 Pt A):2915-2931
pubmed: 30522654
Lancet. 2021 Apr 17;397(10283):1470-1483
pubmed: 33865495
N Engl J Med. 2015 May 7;372(19):1791-800
pubmed: 25773268
Pharmacogenomics J. 2020 Oct;20(5):724-735
pubmed: 32042096
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
Per Med. 2015 Aug;12(4):319-325
pubmed: 29771653
Am J Cardiovasc Drugs. 2022 Mar;22(2):195-206
pubmed: 34490590
Int J Cardiol. 2017 Jun 1;236:54-60
pubmed: 28268087
Int J Pharm Pract. 2013 Dec;21(6):349-61
pubmed: 23683090
J Am Pharm Assoc (2003). 2015 Nov-Dec;55(6):587-594
pubmed: 26409205

Auteurs

Amar D Levens (AD)

Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
ORCID: 0000-0003-2107-4693

Melina C den Haan (MC)

Department of Cardiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

J Wouter Jukema (JW)

Department of Cardiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Netherlands Heart Institute, 3511 EP Utrecht, The Netherlands.
ORCID: 0000-0002-3246-8359

Mette Heringa (M)

SIR Institute for Pharmacy Practice and Policy, 2331 JE Leiden, The Netherlands.
ORCID: 0000-0001-8316-8148

Wilbert B van den Hout (WB)

Department of Biomedical Data Sciences, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Dirk Jan A R Moes (DJAR)

Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Jesse J Swen (JJ)

Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
ORCID: 0000-0002-3965-5552

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Feasibility of Community Pharmacist-Initiated...
Recherchemedicale.com › Maladies cardiovasculaires › Maladies vasculaires › Ischémie myocardique › Syndrome coronarien aigu › Feasibility of Community Pharmacist-Initiated...
Recherchemedicale.com › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Thiénopyridines › Ticlopidine › Clopidogrel › Feasibility of Community Pharmacist-Initiated...
Recherchemedicale.com › Acides aminés, peptides et protéines › Protéines › Hémoprotéines › Cytochromes › Cytochrome P-450 enzyme system › Famille-2 de cytochromes P450 › Limonène hydroxylases › Cytochrome P-450 CYP2C19 › Feasibility of Community Pharmacist-Initiated...
Recherchemedicale.com › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études de faisabilité › Feasibility of Community Pharmacist-Initiated...
Recherchemedicale.com › Phénomènes génétiques › Génotype › Feasibility of Community Pharmacist-Initiated...
Recherchemedicale.com › Établissements, main d'oeuvre et services de soins de santé › Personnel de santé › Pharmaciens › Feasibility of Community Pharmacist-Initiated...
Recherchemedicale.com › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents hématologiques › Antiagrégants plaquettaires › Feasibility of Community Pharmacist-Initiated...
Recherchemedicale.com › Administration des services de santé › Gestion des soins aux patients › Systèmes automatisés lit malade › Feasibility of Community Pharmacist-Initiated...
Recherchemedicale.com › Composés hétérocycliques › Composés hétéromonocycliques › Thiophènes › Chlorhydrate de prasugrel › Feasibility of Community Pharmacist-Initiated...
Recherchemedicale.com › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Ribonucléosides › Adénosine › Ticagrélor › Feasibility of Community Pharmacist-Initiated...
Recherchemedicale.com › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents purinergiques › Antagonistes purinergiques › Antagonistes des récepteurs purinergiques P2 › Antagonistes des récepteurs purinergiques P2Y › Feasibility of Community Pharmacist-Initiated...